- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17:26 | 'Not here to refine the status quo': Excellergy emerges with $70M, plans to redefine allergy therapeutics | ||
| 16:26 | Tvardi's STAT3 inhibitor flunks phase 2 IPF trial amid high dropout rates | ||
| 13:26 | Gilead, Arcus keep TIGIT dream alive with 27-month OS data from phase 2 cancer cohort | ||
| 12:26 | Moderna posts melanoma data behind decision to say 'I do' to IDO | ||
| Fr | Novo shutters cell therapy unit, ending work on potential Type 1 diabetes 'cure' | ||
| Fr | J&J in talks to buy immunology partner Protagonist: WSJ | ||
| Fr | Cabaletta CAR-T wipes out B cells without preconditioning in small autoimmune trial | ||
| Fr | Amid the dip, biotech execs share silver linings in a tumultuous environment | ||
| Fr | AstraZeneca: Building a transparent pipeline from the ground up | ||
| Fr | BMS inks $1.5B in vivo CAR-T buyout to pull Orbital into its sphere of influence | ||
| Fr | Shuttle Pharma launches into AI drug discovery space via $10M acquisition | ||
| Fr | Inflammation biotech Evommune eyes IPO to fund further dermatitis trials | ||
| Do | 2 ex-Moderna leaders unveil $325M inaugural VC fund for platform biotechs | ||
| Do | Ono's BMS-partnered EP4 antagonist improves progression-free survival in phase 2 gastric cancer test | ||
| Do | Expedition resupplies for phase 2 COPD voyage with $165M series A | ||
| Do | AviadoBio secures option to rare eye disease gene therapy that could bring Chinese biotech $413M | ||
| Do | Novo inks Akero buyout worth up to $5.2B to bag late-phase MASH prospect | ||
| Do | CDMO Catalent strengthens ADC pipeline with $10M pact for Lisata tumor drug | ||
| Mi | US government pumps money toward in vivo cell therapy programs | ||
| Mi | TransCode rewrites future, securing $25M lifeline and phase 3 cancer vaccine | ||
| Mi | Arthrosi raises $153M, fueling dash toward phase 3 gout data in 2026 | ||
| Mi | Immunology biotech Nilo launches with $101M and mission to harness neural circuits | ||
| Mi | Sanofi's $110M radioligand therapy hits response rate goal in phase 2 tumor trial | ||
| Di | After high-profile FDA exit, Peter Marks lands at Eli Lilly | ||
| Di | Langer family RNA biotech Soufflé rises with $200M and Big Pharma partners |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .